EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets

Francesco Claps iD, Nicola Pavan iD, Luca Ongaro iD, Domenico Tierno, Gabriele Grassi iD, Carlo Trombetta iD, Gabriele Tulone iD, Alchiede Simonato iD, Riccardo Bartoletti iD, Laura S Mertens, Bas W G van Rhijn, Maria Carmen Mir und 1 weitere

International Journal of Molecular Sciences · 09.08.2023 · 24 (16) · 12596

DOI: 10.3390/ijms241612596 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.08.2023. Verfasst von Francesco Claps und 12 weiteren Autor:innen. Beteiligte Einrichtung: Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Non-Muscle Invasive Bladder Neoplasms, Mycobacterium bovis. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Urothelial carcinoma (UC), the sixth most common cancer in Western countries, includes upper tract urothelial carcinoma (UTUC) and bladder carcinoma (BC) as the most common cancers among UCs (90–95%). BC is the most common cancer and can be a highly heterogeneous disease, including both non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) forms with different oncologic outcomes. Approximately 80% of new BC diagnoses are classified as NMIBC after the initial transurethral resection of the bladder tumor (TURBt). In this setting, intravesical instillation of Bacillus Calmette–Guerin (BCG) is the current standard treatment for intermediate- and high-risk patients. Unfortunately, recurrence occurs in 30% to 40% of patients despite adequate BCG treatment. Radical cystectomy (RC) is currently considered the standard treatment for NMIBC that does not respond to BCG. However, RC is a complex surgical procedure with a recognized high perioperative morbidity that is dependent on the patient, disease behaviors, and surgical factors and is associated with a significant impact on quality of life. Therefore, there is an unmet clinical need for alternative bladder-preserving treatments for patients who desire a bladder-sparing approach or are too frail for major surgery. In this review, we aim to present the strategies in BCG-unresponsive NMIBC, focusing on novel molecular therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCarcinoma, Transitional CellNon-Muscle Invasive Bladder NeoplasmsMycobacterium bovisHumansBCG VaccineQuality of Life

Stichwörter der Autor:innen

Bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancerbladder sparing treatmentchemo-hyperthermiagene therapyimmunotherapynon-muscle-invasive bladder cancerphotodynamic therapy

Substanzen

BCG Vaccine

Autor:innen und Institutionen

  • Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy.
  • Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
  • Department of Surgical, Oncological, and Oral Sciences, University of Palermo, 90127 Palermo, Italy.
  • Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.
  • Department of Medical, Surgery and Health Sciences, Hospital of Cattinara, University of Trieste, Strada di Fiume 447, 34149 Trieste, Italy.
  • Department of Translational Research and New Technologies, University of Pisa, 56126 Pisa, Italy.

ORCID-Profile: Francesco Claps, Nicola Pavan, Luca Ongaro, Gabriele Grassi, Carlo Trombetta, Gabriele Tulone, Alchiede Simonato, Riccardo Bartoletti, Bruna Scaggiante

Zitieren

APA

Claps, F., Pavan, N., Ongaro, L., Tierno, D., Grassi, G., Trombetta, C., Tulone, G., Simonato, A., Bartoletti, R., Mertens, L. S., van Rhijn, B. W. G., Mir, M. C., & Scaggiante, B. (2023). BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets. International Journal of Molecular Sciences, 24(16), 12596. https://doi.org/10.3390/ijms241612596

Vancouver

Claps F, Pavan N, Ongaro L, Tierno D, Grassi G, Trombetta C, et al. BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets. International Journal of Molecular Sciences. 2023;24(16):12596. doi:10.3390/ijms241612596

BibTeX
@article{Claps2023,
  author = {Claps, Francesco and Pavan, Nicola and Ongaro, Luca and Tierno, Domenico and Grassi, Gabriele and Trombetta, Carlo and Tulone, Gabriele and Simonato, Alchiede and Bartoletti, Riccardo and Mertens, Laura S and van Rhijn, Bas W G and Mir, Maria Carmen and Scaggiante, Bruna},
  title = {BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {16},
  pages = {12596},
  doi = {10.3390/ijms241612596}
}
Kostenlos starten →